About MFS-type transporter SLC18B1
MFS-type transporter SLC18B1 (SLC18B1) is a protein
from Homo sapiens identified by UniProt accession
Q6NT16, 456 residues long.
MolForge cross-references it against 0 known binders and
22 disease associations.
Target properties
| Protein name | MFS-type transporter SLC18B1 |
| UniProt accession | Q6NT16 |
| Gene | SLC18B1 |
| Organism | Homo sapiens |
| Length | 456 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (22)
Diseases linked to this target (Open Targets).
- heel bone mineral density · score 0.33
- cortical surface area measurement · score 0.27
- Parkinson disease · score 0.24
- electrocardiography · score 0.22
- DNA methylation · score 0.16
- bone density · score 0.13
- bone quantitative ultrasound measurement · score 0.07
- vitamin B12 deficiency · score 0.06
- metabolite measurement · score 0.02
- ovarian carcinoma · score 0.01
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q6NT16-F1 | alphafold | PREDICTED | 84.61 | — |
Amino-acid sequence (456 residues)
MEALGDLEGP RAPGGDDPAG SAGETPGWLS REQVFVLISA ASVNLGSMMC YSILGPFFPK EAEKKGASNT IIGMIFGCFA LFELLASLVF GNYLVHIGAK FMFVAGMFVS GGVTILFGVL DRVPDGPVFI AMCFLVRVMD AVSFAAAMTA SSSILAKAFP NNVATVLGSL ETFSGLGLIL GPPVGGFLYQ SFGYEVPFIV LGCVVLLMVP LNMYILPNYE SDPGEHSFWK LIALPKVGLI AFVINSLSSC FGFLDPTLSL FVLEKFNLPA GYVGLVFLGM ALSYAISSPL FGLLSDKRPP LRKWLLVFGN LITAGCYMLL GPVPILHIKS QLWLLVLILV VSGLSAGMSI IPTFPEILSC AHENGFEEGL STLGLVSGLF SAMWSIGAFM GPTLGGFLYE KIGFEWAAAI QGLWALISGL AMGLFYLLEY SRRKRSKSQN ILSTEEERTT LLPNET
Explore MFS-type transporter SLC18B1 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets